Acute Effects of Valsartan on Insulin Sensitivity in Obese, Non-Hypertensive Subjects with and without Type 2 Diabetes

Abstract

Background: Two studies were designed to determine whether a single dose (80 mg) of the angiotensin II receptor blocker (ARB), valsartan, alters insulin sensitivity in obese, non-hypertensive subjects with and without Type 2 diabetes. Methods: Insulin sensitivity (S_I), glucose effectiveness (S_G), and acute insulin response (AIR_{0 - 10 min}) were measured by means of a 3-hour insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT) before and after a single dose of valsartan. Study 1: obese, normotensive non-diabetic male subjects (n = 12), mean (SD) age 37.2 ± 11.2 years, BMI 32.8 ± 6.8 kg/m²; Study 2: obese, normotensive Type 2 diabetic patients (n = 12), mean age 55.7 ± 6.9 years, BMI 35.0 ± 6.8 kg/m²/l. Both studies were randomised, double-blind, placebo-controlled, single-dose crossover group studies involving subjects in two study days, two weeks apart. After fasting samples were taken, a 300 mg/kg iv glucose bolus was injected at 0 min, and 0.05 U/kg iv insulin was given 20 min later. Blood samples for analysis of glucose and insulin were taken throughout the 3-hour study period. Results: Study 1 (non-diabetic subjects) S_I 2.81 vs. 2.63 × 10^-4 min^-1 per µU/ml (p = 0.54), S_G 0.020 vs. 0.020 min^-1 (p = 0.90), AIR_{0 - 10 min} 3305 vs. 3450 µU/min/ml (p = 0.71); Study 2 (patients with type 2 diabetes) S_I 0.59 vs. 0.85 × 10^-4 min^-1 per µU/ml (p = 0.15), S_G 0.013 vs. 0.014 min^-1 (p = 0.71), AIR_{0 - 10 min} 65 vs. 119 µU/min/ml (p = 0.14), placebo vs. valsartan, respectively. Conclusion: In obese, non-hypertensive non-diabetic and Type 2 diabetic subjects a single dose of valsartan does not alter insulin sensitivity.

Valsartan - Insulin Sensitivity - Healthy Subjects - Type 2 Diabetes

References

• 1 Reaven G M. Insulin resistance, hyperinsulinaemia and hypertriglyceridaemia in the etiology and clinical course of hypertension. Am J.  Med. 1991;  90 (Suppl. 2) 7-12
• 2 Saad M F, Lillioja S, Nyomba B L, Castillo C, Ferraro R, de Gregorio M, Ravussin E, Knowler W C, Bennett P H, Howard B V, Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. N Engl J.  Med. 1991;  324 733-739
• 3 Manolio T A, Savage P J, Burke G L, Hilner J E, Liu K, Wagenknecht L E, Sidney S, Jacobs D R, Roseman J M, Donahue R P, Oberman A. Association of fasting insulin with blood pressure and lipids in young adults: the CARDIA study.  Arteriosclerosis. 1990;  10 430-436
• 4 Voors A W, Radhakrishnamurthy B, Srinivasan S R, Webber L S, Berenson G S. Plasma glucose level related to blood pressure in 272 children, ages 7 - 15 years sampled from a total biracial population. Am J.  Epidemiol. 1981;  113 347-356
• 5 Haffner S M, Fong D, Hazuda H P, Pugh J A, Patterson J K. Hyperinsulinaemia, upper body adiposity and cardiovascular risk factors in non-diabetics.  Metabolism. 1988;  37 338-345
• 6 Laakso M, Surland H, Mykkanen L. Essential hypertension and insulin resistance in non-insulin dependent diabetes. Eur J Clin.  Invest. 1989;  19 518-526
• 7 Collins V R, Dowse G K, Finch C F, Zimmet P Z. An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin.  Epidemiol. 1990;  43 1369-1378
• 8 Kahn S E, Prigeon R L, McCullough D K, Boyko E J, Bergman R N, Schwartz M W, Neifing J L, Ward W K, Beard J C, Palmer J P, Porte D . Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.  Diabetes. 1993;  42 1663-1672
• 9 Clausen J O, Borch-Johnsen K, Ibsen H, Bergman R N, Hougaard P, Winther K, Pedersen O. Insulin sensitivity index, acute insulin response and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. J Clin.  Invest. 1996;  98 1195-1209
• 10 Haffner S M, Howard G, Mayer E, Bergman R N, Savage P J, Rewers M, Mykkanen L, Karter A J, Hamman R, Saad M F. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites and Hispanics with NIDDM: The Insulin Resistance Atherosclerosis Study.  Diabetes. 1997;  46 63-69
• 11 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico M A, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J.  Med. 1987;  317 350-357
• 12 Stumvoll M, Fritsche A, Stefan N, Häring H. A 60-minute hyperglycaemic clamp is sufficient to assess both phases of insulin secretion.  Horm Metab Res. 2000;  32 230-232
• 13 Stumvoll M, Wahl H G, Löblein K, Becker R, Volk A, Renn W, Jacob S, Häring H. A novel use of the hyperinsulinemic-euglycemic clamp technique to estimate insulin sensitivity of systemic lipolysis.  Horm Metab Res. 2001;  33 89-95
• 14 Walton C, Godsland I F, Proudler A J, Felton C V, Wynn V. Effect of body mass index and fat distribution on insulin sensitivity, secretion and clearance in nonobese healthy men. J Clin Endocrinol.  Metab. 1992;  75 170-175
• 15 Moan A, Risanger T, Eide I, Kjeldsen S E. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.  Blood Pressure. 1994;  3 185-188
• 16 Moan A, Hoieggen A, Nordby G, Eide I K, Kjeldsen S E. Effects of losartan on insulin sensitivity in severe hypertension; connections through sympathetic nervous system activity?.  J Human Hypertension. 1995;  9 (Suppl. 5) S45-50
• 17 Paolisso G, Tagliamonte M R, Gambardella A, Manzella D, Gualaiero P, Varricchio G, Verza M, Varricchio M. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.  J Human Hypertension. 1997;  11 307-312
• 18 Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of an angiotensin II receptor anatagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension.  J Human Hypertension. 1999;  13 (Suppl. 1) S71-74
• 19 Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects.  Hypertension. 1996;  28 392-396
• 20 Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparitive effects of lisinopril and losartan on insulin sensitivity in the treatment of non hypertensive patients.  Br J Clin Pharmacol. 1998;  46 467-471
• 21 Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, Lusardi P. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.  J Cardiovasc Pharmacol. 1998;  32 616-620
• 22 Lerch M, Teuscher A U, Beissner P, Schneider M, Shaw S G, Weidmann P. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive patients.  J Cardiovasc Pharmacol. 1998;  31 576-580
• 23 Bergman R N, Ider Y Z, Bowden C R, Cobelli C. Quantitative estimation of insulin sensitivity. Am J.  Physiol. 1979;  236 E667-E677
• 24 Lithell H O. Insulin resistance and diabetes in the context of treatment of hypertension. Blood P N Engl J.  Med Pressure. 1998;  7 (Suppl. 3) 28-31
• 25 Pollare T, Lithiell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.  N Engl J Med. 1989;  321 868-873
• 26 Iimura O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura K, Miyazaki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor anatagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives.  Amer J Hypertens. 1995;  8 353-357
• 27 Sasaki K, Kushiro T, Nakagawa S, Kanmatsuse K. Effects of angiotensin II receptor anatagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats.  Japanese Journal of Nephrology. 1999;  41 692-696